3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Stomach Neoplasms
7
Gastritis
5
Peptic Ulcer
3
Gastroesophageal Reflux
3
Dyspepsia
3
Breast Neoplasms
3
Barrett Esophagus
3
Stomach Ulcer
2
Colorectal Neoplasms
2
Vomiting
1
Radiation Esophagitis
1
Precancerous Conditions
1
Peptic Ulcer Hemorrhage
1
Neoplasm Metastasis
1
Nausea
1
Lymphoma, B-Cell, Marginal Zone
1
Hemorrhage
1
Head and Neck Neoplasms
1
Gastrointestinal Stromal Tumors
1
Gastritis Dyspepsia Helicobacter Pylori Infection Gastric Cancer Peptic Ulcer
1
Esophagitis
1
Esophageal Neoplasms
1
Dysbiosis
1
Colonic Neoplasms
1
Interventions
Imatinib Mesylate
32
regorafenib
9
Sunitinib
9
Laparoscopy
5
Dasatinib
4
Blood Specimen Collection
4
pazopanib
3
nilotinib
3
Surveys and Questionnaires
3
Surgical Procedures, Operative
3
Paclitaxel
3
Observation
3
spartalizumab
2
ripretinib
2
envafolimab
2
binimetinib
2
apatinib
2
Temozolomide
2
Neoadjuvant Therapy
2
Ipilimumab
2
Gemcitabine
2
Docetaxel
2
Cisplatin
2
Carboplatin
2
Capecitabine
2
CTLA-4 Antigen
2
Biopsy, Fine-Needle
2
Biopsy
2
5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide
2
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Gastrointestinal Stromal Tumors
×
Esomeprazole
×
Clear all
NCT02800330
2018-08-02
REGORA
Erasmus Medical Center
Phase 4
Completed
31 enrolled